A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults with Major Depressive Disorder
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Major Depressive Disorder
Спонсор: Draig Therapeutics Limited
Налично на:
БГ
Обобщение
Trial status: Authorised
This will be assessed by reviewing the change in the participants score of the depression rating scale called Montgomery Åsberg Depression Rating Scale (MADRS)
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 113 participants
БГ
EN